Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

39results about How to "Inhibition of chemotaxis" patented technology

Antikine antibodies that bind to multiple cc chemokines

An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES / CCL5, MIP-1α / CCL3, MIP-1β / CCL4, or MCP-1 / CCL2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producing antikine antibodies by sequential immunization are also disclosed.
Owner:VLST +1

Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine

There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there can be provided an antibody drug for suppressing chemotaxis and cytotoxic activity of killer lymphocytes by suppressing an interaction between CX3CR1 and fractalkine.
Owner:EISIA R&D MANAGEMENT CO LTD

Giant salamander Chinese herbal medicine compound preparation for treating hepatitis B

The invention relates to a giant salamander Chinese herbal medicine compound preparation for treating hepatitis B. The preparation is prepared from giant salamander tissue and the following Chinese herbal medicines in parts by weight: 35-45 parts of medlar, 25-35 parts of lucid ganoderma, 10-14 parts of coptis chinensis, 13-16 parts of radix sophorae flavescentis, 10-14 parts of selfheal, 13-16 parts of radix scutellariae, 16-20 parts of isatis roots, 16-20 parts of honeysuckles, 8-12 parts of dendrobium officinale and 6-10 parts of ginseng, wherein the giant salamander tissue comprises 500-3000 parts of giant salamander liver and 5-9 giant salamander gallbladders. The preparation method of the preparation comprises the following steps: grinding and mixing the giant salamander tissue, steaming for 8-12 minutes at 85-95 DEG C and freezing to obtain a giant salamander tissue mixture; smashing medlar, lucid ganoderma, coptis chinensis, radix sophorae flavescentis, selfheal, radix scutellariae, isatis roots, honeysuckles, dendrobium officinale, ginseng and spiral seaweed to obtain a Chinese herbal medicine mixture; and mixing the giant salamander tissue mixture with the Chinese herbal medicine mixture. The preparation provided by the invention not only has a good antiviral performance, but also can effectively enhance the antigen binding affinity and the immunity to protect liver activity and promote recovery of damaged liver cells and the like. The preparation for treating hepatitis B is remarkable in curative effect.
Owner:张家界金鲵生物工程股份有限公司

Novel biphenyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases comprising the same as active ingredient

The present invention relates to a novel biphenyl derivative or a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases comprising the same as an active ingredient, and methods for treating inflammatory disease or autoimmune diseases with the pharmaceutical composition. Novel biphenyl derivatives according to the present invention promote the phagocytosis of macrophages and inhibit the chemotaxis to exhibit excellent inflammation terminating and anti-inflammatory effects and thus can be effectively used as therapeutic agents for inflammatory diseases or autoimmune diseases.
Owner:DONGGUK UNIV IND ACADEMIC COOPERATION FOUND

Application of oligochitosan in preparing medicine for preventing from formation of atherosclerosis

The invention relates to a medicine for curing atherosclerosis, in particular to application of oligochitosan in preparing a medicine for preventing from the formation of atherosclerosis. The application takes lipopolysaccharide (lipopolysaccharide) and humanized gene recombinant tumor necrosis factor-alpha (TNF-alpha) as an induction factor, and takes human umbilical vein endothelial cell as a research object, thereby having the following results: (1) the oligochitosan can obviously restrain the expressions of IL-8, IL-6 and relevant inflammatory factors in the lipopolysaccharide-induced human umbilical vein endothelial cell; (2) the oligochitosan can obviously restrain the expressions of membrane surface molecules VCAM-1. ICAM-1 and relevant adhesion molecules family members of the TNF-alpha-induced human umbilical vein endothelial cell; and (3) the oligochitosan can obviously restrain the adhesion between the TNF-alpha-induced human umbilical vein endothelial cell and the human mononuclear cell.
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI

Antikine antibodies that bind to multiple CC chemokines

An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES / CCL5, MIP-1α / CCL3, MIP-1β / CCL4, or MCP-1 / CCL2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producing antikine antibodies by sequential immunization are also disclosed.
Owner:VLST +1

C5aR antibody, preparation method and application thereof

The invention discloses a C5aR antibody, a preparation method and an application thereof. The C5aR antibody comprises one or more of a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 in a heavy-chain variable region, and one or more of a light chain CDR1, a light chain CDR2 and a light chain CDR3 in a light-chain variable region. The C5aR antibody has the advantages that the affinity for a human-derived C5aR protein is high, the combination of the C5aR protein and C5a can be effectively prevented, so that corresponding signal channels are descended or cut off, and directional migration of C5a of in-vitro neutrophil is stopped; and the chemotactic effect of the neutrophil can be obviously inhibited. Therefore, the C5a antibody can be applied to preparation of medicines for treating inflammations, vascular diseases or nervous system diseases and the like.
Owner:SHANGHAI YUNYI HEALTHCARE MANAGEMENT

Naturally occurring IgM antibodies that bind lymphocytes

InactiveUS20080112950A1Inhibits Hepatitis CInhibit binding of chemokinesVertebrate antigen ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsHeterologousLymphocyte Antibody
Human and animal serum contains naturally occurring autoantibodies that develop at birth in absence of deliberate immunization. These antibodies are predominantly of IgM isotype but can include all immunoglobulin isotypes such as IgD, IgA and IgG. Here we describe IgM anti-lymphocyte autoantibodies (IgM-ALA) and show that these antibodies are heterogenous with some antibodies binding to chemokine receptors such as CCR5 and CXCR4 and others binding to other lymphocyte receptors including CD3, CD2, CD4 and CD81. These IgM-ALA, unlike IgG antibodies, are not cytolytic to cells at 37 C and hence function to alter lymphocyte function including cytokine production and act as “blocking antibodies to inhibit binding of chemokines and viruses including HIV-1 and Hepatitis C. IgM antibodies that bind to receptors on lymphocyte also bind to the same or similar class of receptors on other leucocytes and other cells such as cancer cells and endothelial cells. The inventor claims that naturally occurring anti-lymphocyte antibodies inhibit viral infections, cancer and several inflammatory states by binding to chemokine receptors and other cell membrane receptors that activate cells or promote viral entry and replication. Inventor also claims methods for quantitating levels of IgM-ALA with different receptor specificities to aid in preventing disease progression and also claims methods to enhance in-vivo or in-vitro production of IgM-ALA.
Owner:LOBO

Naturally occuring IgM antibodies that bind lymphocytes

Human and animal serum contains naturally occurring autoantibodies that develop at birth in absence of deliberate immunization. These antibodies are predominantly of IgM isotype but can include all immunoglobulin isotypes such as IgD, IgA and IgG. Here we describe IgM anti-lymphocyte autoantibodies (IgM-ALA) and show that these antibodies are heterogenous with some antibodies binding to chemokine receptors such as CCR5 and CXCR4 and others binding to other lymphocyte receptors including CD3, CD2, CD4 and CD81. These IgM-ALA, unlike IgG antibodies, are not cytolytic to cells at 37 C and hence function to alter lymphocyte function including cytokine production and act as “blocking antibodies to inhibit binding of chemokines and viruses including HIV-1 and Hepatitis C. IgM antibodies that bind to receptors on lymphocyte also bind to the same or similar class of receptors on other leucocytes and other cells such as cancer cells and endothelial cells. The inventor claims that naturally occurring anti-lymphocyte antibodies inhibit viral infections, cancer and several inflammatory states by binding to chemokine receptors and other cell membrane receptors that activate cells or promote viral entry and replication. Inventor also claims methods for quantitating levels of IgM-ALA with different receptor specificities to aid in preventing disease progression and also claims methods to enhance in-vivo or in-vitro production of IgM-ALA.
Owner:LOBO

VHH (variable domain of heavy chain of heavy-chain antibody) antibody gene derived from anti-CyPA (CyclophilinA) animal of family Camelidae, encoded polypeptide, and application thereof

The invention relates to VHH (variable domain of heavy chain of heavy-chain antibody) antibody gene derived from anti-CyPA (CyclophilinA) animal of family Camelidae, encoded polypeptide, and application of the gene and the polypeptide in preparing drugs for treating inflammatory diseases such as rheumatoid arthritis. The VHH antibody gene has gene sequence shown in sequence table (400)1, the encoded polypeptide has amino acid sequence shown in sequence table (400)2. Lama pacos as immune animal is used, and phage display techniques (PDT) are adopted to successfully obtain an anti-CyPA VHH antibody capable of specifically combining with expressed CyPA antigen. The antibody can inhibit monocytes THP-1 chemotaxis and gelatinase secretion induced by CyPA. Dimer or polymer can be constructed by gene engineering method, to be applied in diagnosis or research on drugs for treating inflammatory diseases. The gene and the polypeptide establish foundation for further research on related drugs for treating rheumatoid arthritis.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Long-ncting heparin intraocular slow-released system

The present invention provides a long-acting heparin intraocular slow-releasing system, including heparin and medicinal carrier; their weight ratio is 0.1:0.9-0.9:0.1. Said medicinal carrier can be synthetic biodegradable high-molecular material, natural biodegradable high-molecular material or their mixture. The medicine-releasing period of said invented long-acting heparin slow-releasing systemis one week to one year. It can be used for inhibiting formation of antithrombase, resisting conversion of fibrinogen into insoluble fibrin, inhibiting proliferation and chemotaxis of fibrolast, reducing postoperative fibrinous exudation and preventing postcapsule opacity so as to inhibit the production of after-cataract.
Owner:INST OF CHEM CHINESE ACAD OF SCI +1

Oral giant salamander liquid for brain strengthening, and preparation method thereof

The invention provides an oral giant salamander liquid for brain strengthening. The oral liquid is prepared through using the following raw materials, by weight, 150-250 parts of a giant salamander brain, 10-20 parts of a giant salamander liver, 4-8 parts of ginseng, 15-25 parts of Lycium Chinense, 25-35 parts of lotus seed, 8-12 parts of brown sugar, 8-12 parts of walnut kernel, 15-25 parts of Dioscorea opposita and 15-25 parts of red date. A preparation method of the oral liquid comprises the following steps: adding water having a weight 2-3 times raw materials except brown sugar to the raw materials except brown sugar, decocting with a slow fire for 1.5-2h, filtering, adding brown sugar, uniformly mixing, filtering, cooling, and canning. The oral liquid has the efficacies of essence replenishing, blood tonifying, brain strengthening, intelligence developing, liver and kidney nourishing, heart fire clearing, vexation eliminating, qi tonifying, blood nourishing and the like, and can be adapted to all age groups.
Owner:张家界金鲵生物工程股份有限公司

Anti-inflammatory application of small molecule compound AG-4

The invention discloses anti-inflammatory application of a small molecule compound AG-4, and application in preparing anti-inflammatory drug. The small molecule compound AG-4 is screened through a candidate drug screening platform combining structural biology, information biology and biological activity determination. The small molecule compound AG-4 can realize specific binding with CD147 protein to inhibit inflammatory cell chemotaxis and secretion of chemotaxis; the invention is also suitable for preparing medicines for treating CD147 protein high expression related diseases (such as rheumatoid arthritis).
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Aquaporin 4-siRNA interfering sequence, its fusion expression vectors and medicinal use of the fusion expression vectors

InactiveCN102242117AInhibited DiffusionInhibition of invasion and infiltrationNervous disorderGenetic material ingredientsHuman gliomaWilms' tumor
The invention discloses an aquaporin 4-siRNA interfering sequence, its fusion expression vectors and a medicinal use of the fusion expression vectors, and belongs to the biopharmaceutical field. In the invention, an aquaporin 4-siRNA interfering sequence is designed and fusion expression vectors of the aquaporin 4-siRNA interfering sequence are synthesized. After the fusion expression vectors are transfected into human glioma cell lines, the fusion expression vectors can degrade specifically aquaporin 4mRNA which is complementary with the fusion expression vectors, decrease the expression of an aquaporin protein 4 in a human glioma cell, inhibit effectively a migration capacity, an adhesive capacity and an invasion capacity of human glioma cells and have effects of inhibiting the infiltration and the diffusion of human glioma cells thus provide a feasible technical means for a gene therapy utilized for tumor patients.
Owner:TIANJIN MEDICAL UNIV CANCER HOSPITAL

Composition capable of enabling skin to defend pigments, and application

The invention discloses a composition capable of enabling the skin to defend pigments, and application. The composition comprises 1-4% of glutathione, 1-3% of arbutin, 0.2-0.6% of vitamin C, 0.1-2% ofvitamin E, 0.05-0.1% of indomethacin, 0.01-0.05% of 9-carotene, 0.1-0.6% of green tea, 0.2-0.7% of fructus mume extract, 0.2-0.9% of cortex cinnamomi extract, 2-12% of glycyrrhizae radix oil, 1-6% ofsoluble extract and the balance of water. Since the glutathione and the arbutin are added, formation of melanin is inhibited and disturbed so as to reduce skin pigment deposition and remove colored patches and freckles, the vitamin C, the vitamin E, the fructus mume extract and the soluble extract are combined to increase oxidation resistance capacity, the composition is prevented from being oxidized, the composition is guaranteed to still own an effect of inhibiting the formation of the melanin in the sun, and the skin fully defends the pigments.
Owner:珂蓝(重庆)化妆品有限公司

Long-acting low molecule heparin intraocular sustained-release system

The invention relates to an ophthalmic controlled release system of long-action low molecular heparin which comprises the low molecular heparin as drug and a drug carrier made from synthesized or natural biodegradable high molecular materials and is characterized in that the proportion range of the low molecular heparin and the drug carrier is (1:8) to (5:1); the average molecular mass of the lowmolecular heparin is less than 8000 Dalton; the molecules less than 8000 Dalton, the salt compounds of the low molecular heparin such as sodium salt, calcium salt and kali salt included, take up not less than 60 percent of the total molecules of the low molecular heparin; the synthesized or natural biodegradable high molecular materials are polyglycolic acid and gelatin or bletilia striata gelatinrespectively. The ophthalmic controlled release system of long-action low molecular heparin can effectively inhibit the proliferation and migration of lenticular epithelia and fibroblasts in eyes, reduce fibrinous exudates post operation, alleviate inflammatory reaction post operation and prevent posterior capsular opacification, thereby inhibiting the occurrence of after-cataract; meanwhile, theophthalmic controlled release system of long-action low molecular heparin inhibits the proliferation of retinal pigment epithelium and fibroblasts, thus inhibiting the proliferative vitreoretinopathy(PVR).
Owner:SHANDONG EYE INST

N-terminal recombinant protein of ccr4 and use thereof

The present invention provides a recombinant protein or a derivative thereof, wherein the recombinant protein has an amino acid sequence of the N-terminal portion of CC chemokine receptor 4 (CCR4). The invention also provides the use of the recombinant protein or a derivative thereof for treating or preventing a disease or condition associated with CCR4 signaling.
Owner:INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES

Oral Andrias davidianus liquid for eyesight improvement, and preparation method thereof

The invention provides an oral Andrias davidianus liquid for eyesight improvement. The oral liquid is prepared through using the following raw materials, by weight, 6-10 parts of an Andrias davidianus eye, 8-12 parts of an Andrias davidianus liver, 40-60 parts of Andrias davidianus skin, 8-12 parts of Lycium Chinense, 8-12 parts of wild chrysanthemum flower, 8-12 parts of white peony root, 18-22 parts of unprepared rehmannia root, 8-12 parts of honey, and 8-12 parts of morchella. A preparation method of the oral liquid comprises the following steps: adding water having a weight 2-3 times the raw materials except honey to the raw materials except honey, decocting with a slow fire for 1.5-2h, filtering, adding honey, uniformly mixing, cooling, and canning to obtain the oral Andrias davidianus liquid for eyesight improvement. The oral Andrias davidianus liquid has the efficacies of liver cleaning, eyesight improving, kidney yin nourishing and the like, and can improve the organism immunity, promote the brain development, prevent senile dementia, protect the eyesight and delay ageing through frequent drinking.
Owner:张家界金鲵生物工程股份有限公司

Oral Andrias davidianus liquid for eyesight improvement, and preparation method thereof

The invention provides an oral Andrias davidianus liquid for eyesight improvement. The oral liquid is prepared through using the following raw materials, by weight, 6-10 parts of an Andrias davidianus eye, 8-12 parts of an Andrias davidianus liver, 40-60 parts of Andrias davidianus skin, 8-12 parts of Lycium Chinense, 8-12 parts of wild chrysanthemum flower, 8-12 parts of white peony root, 18-22 parts of unprepared rehmannia root, 8-12 parts of honey, and 8-12 parts of morchella. A preparation method of the oral liquid comprises the following steps: adding water having a weight 2-3 times the raw materials except honey to the raw materials except honey, decocting with a slow fire for 1.5-2h, filtering, adding honey, uniformly mixing, cooling, and canning to obtain the oral Andrias davidianus liquid for eyesight improvement. The oral Andrias davidianus liquid has the efficacies of liver cleaning, eyesight improving, kidney yin nourishing and the like, and can improve the organism immunity, promote the brain development, prevent senile dementia, protect the eyesight and delay ageing through frequent drinking.
Owner:张家界金鲵生物工程股份有限公司

Preparation method of medical adhesive with efficient anti-inflammation and bleeding-stopping functions

The invention discloses a preparation method of a medical adhesive with efficient anti-inflammation and bleeding-stopping functions. The medical adhesive is characterized by containing the following components in parts by weight: 20-25 parts of alpha-octyl cyanoacrylate, 25-35 parts of alpha-isoctyl cyanoacrylate, 2-6 parts of polyvinyl acetate, 12-20 parts of an efficient anti-inflammation component, 13-23 parts of an efficient bleeding-stopping component, 3-6 parts of a cell activator MG-60, 8-10 parts of allantoin, 1 part of hydrolyzed wheat proteins, 1 part of a stabilizer, 150-220 parts of a compound anti-inflammation fruit oil component and 200 parts of sterile water. By particularly selecting multiple extracts with the anti-inflammation and bleeding-stopping functions and adding twoefficient anti-inflammation components and one efficient bleeding-stopping component, the integral anti-inflammation and bleeding-stopping effects of the medical adhesive are improved, and the medical adhesive is high in bonding strength, short in bleeding-stopping time and accordant with clinical application requirements on medical adhesives.
Owner:浙江派菲特新材料科技有限公司

Medical adhesive with efficient anti-inflammation and hemostasis functions

The invention discloses a medical adhesive with efficient anti-inflammation and hemostasis functions. The medical adhesive is characterized by comprising, by weight, 20-25 parts of alpha-N-octyl cyanoacrylate, 25-35 parts of alpha-isooctyl cyanoacrylate, 2-6 parts of polyvinyl acetate, 12-20 parts of efficient anti-inflammation components, 13-23 parts of efficient hemostasis components, 3-6 partsof cell activators MG-60, 8-10 parts of allantoin, 1 part of hydrolyzed wheat protein, 1 part of stabilizers, 150-220 parts of compound anti-inflammatory fruit oil components and 200 parts of sterilewater. The medical adhesive particularly selects various extracts with the anti-inflammation and hemostasis functions, two efficient anti-inflammation components and one efficient hemostasis componentare added, so that overall anti-inflammation and hemostasis effects are improved, and the medical adhesive is high in bonding strength and short in hemostasis time and meets application requirementsof clinical medical adhesives.
Owner:浙江派菲特新材料科技有限公司

Anti-inflammatory application of small molecule compound AG-4

The invention discloses anti-inflammatory application of a small molecule compound AG-4, and application in preparing anti-inflammatory drug. The small molecule compound AG-4 is screened through a candidate drug screening platform combining structural biology, information biology and biological activity determination. The small molecule compound AG-4 can realize specific binding with CD147 protein to inhibit inflammatory cell chemotaxis and secretion of chemotaxis; the invention is also suitable for preparing medicines for treating CD147 protein high expression related diseases (such as rheumatoid arthritis).
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

A kind of suppository with good anti-inflammatory, analgesic and hemostatic effects and preparation method thereof

The invention discloses a medicinal suppository with good anti-inflammatory, analgesic and hemostatic effect and a preparation method. It is prepared from the following components by weight: 2 to 15 parts of Guizhi, 2 to 15 parts of Yuanhu, and 5 to 5 parts of Diyu. 16. Acorus 2 to 10, Borneol 2 to 10, Fangfeng 2 to 10, Galla chinensis 1 to 10, Angelicae 2 to 12, Notoginseng 2 to 12, Indomethacin 2 to 16. The invention effectively solves the problems of high toxic and side effects of Western medicine alone and poor therapeutic effect of Chinese medicine alone. It highlights the effects of antispasmodic and analgesic, anti-inflammatory and detoxification, activating blood circulation and removing blood clots, hemostasis and replenishing blood, etc., and chooses anorectal administration. At the same time, combined with the penetrating effect of aromatic resuscitation drugs, the active ingredients of the drug are transmitted to various tissues and organs through the meridians to regulate moistening. It nourishes the body and reduces the damage caused by western medicine to the gastrointestinal, liver, kidney, heart and brain and other organs. It is easy to administer, fast absorbed, quick to take effect, good analgesic effect, less toxic and side effects, non-addictive, non-dependent, safe and reliable , is an ideal antispasmodic, analgesic, blood circulation promoting, hemostatic and anti-inflammatory suppository.
Owner:薛保玉

VHH (variable domain of heavy chain of heavy-chain antibody) antibody gene derived from anti-CyPA (CyclophilinA) animal of family Camelidae, encoded polypeptide, and application thereof

The invention relates to VHH (variable domain of heavy chain of heavy-chain antibody) antibody gene derived from anti-CyPA (CyclophilinA) animal of family Camelidae, encoded polypeptide, and application of the gene and the polypeptide in preparing drugs for treating inflammatory diseases such as rheumatoid arthritis. The VHH antibody gene has gene sequence shown in sequence table (400)1, the encoded polypeptide has amino acid sequence shown in sequence table (400)2. Lama pacos as immune animal is used, and phage display techniques (PDT) are adopted to successfully obtain an anti-CyPA VHH antibody capable of specifically combining with expressed CyPA antigen. The antibody can inhibit monocytes THP-1 chemotaxis and gelatinase secretion induced by CyPA. Dimer or polymer can be constructed by gene engineering method, to be applied in diagnosis or research on drugs for treating inflammatory diseases. The gene and the polypeptide establish foundation for further research on related drugs for treating rheumatoid arthritis.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Application of a kind of ethyl ketone compound in preparation of medicine for treating inflammation

The invention discloses 1-(5-(3-((4-chlorobenzyl)amino)-2-hydroxypropoxy)-2-methyl-1-(p-tolyl)-1hydro-indole- 3-yl) ethyl ketone for the treatment or prevention of inflammatory diseases, for the prevention and / or alleviation and / or auxiliary treatment and / or treatment of inflammatory diseases, such as bronchitis, pneumonia, hepatitis, rhinitis, enteritis, gastritis , nephritis, dermatitis, prostatitis, vaginitis, rheumatism, etc. The present invention 1-(5-(3-((4-chlorobenzyl) amino)-2-hydroxypropoxy)-2-methyl-1-(p-tolyl)-1 hydrogen-indole-3- Base) ethyl ketone has specific inhibitory effect on PI3Kγ, and has inhibitory effect on inflammatory cell proliferation and chemotaxis. The compound of the present invention can inhibit inflammatory response by inhibiting PI3Kγ.
Owner:CF PHARMTECH

A medical glue with high-efficiency anti-inflammatory and hemostatic functions

The invention discloses a medical adhesive with efficient anti-inflammation and hemostasis functions. The medical adhesive is characterized by comprising, by weight, 20-25 parts of alpha-N-octyl cyanoacrylate, 25-35 parts of alpha-isooctyl cyanoacrylate, 2-6 parts of polyvinyl acetate, 12-20 parts of efficient anti-inflammation components, 13-23 parts of efficient hemostasis components, 3-6 partsof cell activators MG-60, 8-10 parts of allantoin, 1 part of hydrolyzed wheat protein, 1 part of stabilizers, 150-220 parts of compound anti-inflammatory fruit oil components and 200 parts of sterilewater. The medical adhesive particularly selects various extracts with the anti-inflammation and hemostasis functions, two efficient anti-inflammation components and one efficient hemostasis componentare added, so that overall anti-inflammation and hemostasis effects are improved, and the medical adhesive is high in bonding strength and short in hemostasis time and meets application requirementsof clinical medical adhesives.
Owner:浙江派菲特新材料科技有限公司

Aromatic amine ketone compounds, its synthesis method, pharmaceutical composition containing same and uses

The invention provides arylamine ketone compounds having a general formula (I), the preparation of the compound, the medicinal composition containing them and the use of these compounds in preventing and / or treating platelet activating factor related diseases, especially the use in antiphlogistic immunization, in particular for treating acute or chronic inflammation, such as osteoarthritis, chronic infectious arthritis etc.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI

N-terminal recombinant protein of CCR4 and use thereof

The present invention provides a recombinant protein or a derivative thereof, wherein the recombinant protein has an amino acid sequence of the N-terminal portion of CC chemokine receptor 4 (CCR4). The invention also provides the use of the recombinant protein or a derivative thereof for treating or preventing a disease or condition associated with CCR4 signaling, such as an allergic disease, inflammatory enteritis, psoriasis, an inflammatory skin disease, vasculitis, spondyloarthropathy, scleroderma, asthma, a respiratory allergic disease, an autoimmune disease, graft rejection, leukemia, lymphoma, a blood-borne cancer, a disease requiring inhibition of undesirable inflammation, and a cancer.
Owner:INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products